Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Manage your formulary budget
Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Orphan drug exclusivity is granted to drugs addressing rare 'orphan diseases' — those affecting fewer than 200,000 Americans.
The protection granted to orphan drugs is quite strong. The FDA is barred from approving any other biologic or small-molecule drug, generic/follow-on or otherwise, treating the same orphan disease for seven years.
This chart shows the companies which have received the most orphan drug exclusivities in the past five years.
The companies with the most orphan drug approvals are: